<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01031095</url>
  </required_header>
  <id_info>
    <org_study_id>BYİEAH1</org_study_id>
    <nct_id>NCT01031095</nct_id>
  </id_info>
  <brief_title>(A Novel Pharmacologic Regime for Elective Percutaneous Coronary Intervention)</brief_title>
  <acronym>REDUCED</acronym>
  <official_title>A RandomisED StUdy Comparing Standard Systemic Anticoagulation ThErapy to Low Dose Intracoronary Anticoagulation Therapy for Elective Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bursa Postgraduate Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bursa Postgraduate Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis:

      Low dose intracoronary unfractionated heparin is as effective and safe as standard dose
      intravenous unfractionated heparin on patients with elective percutaneous coronary
      intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim:

      Primary objective:To evaluate the efficiency and safety of low dose intracoronary
      unfractioned heparin (UFH) on elective percutaneous coronary intervention (PCI).

      Secondary objective:

        -  To evaluate the effect of low dose intracoronary UFH on myocardial ischemia after PCI.

        -  To evaluate the effect of low dose intracoronary UFH on bleeding complications after
           PCI.

        -  To evaluate the cost-effectivity of low dose intracoronary UFH on elective PCI

      Study central:

        -  Bursa Postgraduate Hospital, Cardiology Clinic

      Study population:

        -  we planned to enrol 200 patients.

        -  Patients will randomise in two groups (control group:100 patients, study group:100
           patients)

      Study works:-Write case report form for all patients

        -  Control for inclusion criteria

        -  Demographic data (age, gender)

        -  Height, weight, BMI and glomerular filtration rate (GFR)

        -  Risk factors

        -  laboratory data (biochemical and hematologic)

        -  Medication history

        -  Echocardiographic data

        -  Angiographic data

        -  Procedure time

        -  PCI data(vessel diameter, stent diameter, lesion and stent length, performed
           percutaneous transluminal coronary angioplasty (PTCA) or not, etc)

        -  Before and after procedure (activated clotting time) ACT value

        -  Before and after procedure troponin I (TnI) and Creatine kinase MB (CKMB) levels

        -  Note complication (MACE, bleeding, hematoma etc)

        -  Note femoral compression time.

           4 weeks later note the first control data.

      Six months later note the second control data.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiac Events</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Adverse Cardiac Event</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Low dose intracoronary heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose intracoronary heparin: In this group elective coronary intervention was performed with low dose intracoronary Heparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment arm: In this group elective coronary intervention performed with standard dose intravenous heparin</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>coronary intervention</intervention_name>
    <description>elective coronary intervention</description>
    <arm_group_label>Low dose intracoronary heparin</arm_group_label>
    <arm_group_label>Standard treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patients; who have planned elective PCI and have had written informed consent for
             participation to study.

          -  The native coronary artery;

               -  lesion with narrowing &gt;=70%,

               -  lesion without thrombus

               -  no left main coronary artery (LMCA) lesion

               -  no chronic total occlusion lesion

        Exclusion Criteria:

          -  Patients have allergy for acetylsalicylic acid (ASA), Clopidogrel and heparin

          -  Patients who performed primary PCI

          -  Patients with acute coronary syndrome

          -  Patients with have a history of myocardial infarction (MI) for two weeks

          -  Patients who were use UFH or low molecular weight heparin (LMWH) for 24 hours

          -  Patients on warfarin therapy

          -  Patients who have bleeding diathesis, or have high risk for bleeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hasan Arı, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bursa Postgraduate Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi</name>
      <address>
        <city>Bursa</city>
        <zip>16320</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Stabile E, Nammas W, Salemme L, Sorropago G, Cioppa A, Tesorio T, Ambrosini V, Campopiano E, Popusoi G, Biondi Zoccai G, Rubino P. The CIAO (Coronary Interventions Antiplatelet-based Only) Study: a randomized study comparing standard anticoagulation regimen to absence of anticoagulation for elective percutaneous coronary intervention. J Am Coll Cardiol. 2008 Oct 14;52(16):1293-8. doi: 10.1016/j.jacc.2008.07.026.</citation>
    <PMID>18929239</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2009</study_first_submitted>
  <study_first_submitted_qc>December 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2009</study_first_posted>
  <results_first_submitted>January 21, 2012</results_first_submitted>
  <results_first_submitted_qc>July 24, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 10, 2013</results_first_posted>
  <last_update_submitted>December 24, 2013</last_update_submitted>
  <last_update_submitted_qc>December 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bursa Postgraduate Hospital</investigator_affiliation>
    <investigator_full_name>Hasan ARI</investigator_full_name>
    <investigator_title>Bursa Postgraduate Hospital</investigator_title>
  </responsible_party>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>low dose intracoronary heparin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low Dose Intracoronary Heparin</title>
          <description>Low dose intracoronary heparin treatment arm</description>
        </group>
        <group group_id="P2">
          <title>Standard Therapy</title>
          <description>standard unfractionated heparin (UFH) treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Dose Intracoronary Heparin</title>
          <description>Low dose intracoronary heparin treatment arm</description>
        </group>
        <group group_id="B2">
          <title>Standard Therapy</title>
          <description>standard UFH treatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.11" spread="9.68"/>
                    <measurement group_id="B2" value="58.99" spread="11.24"/>
                    <measurement group_id="B3" value="59.06" spread="10.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Major Adverse Cardiac Events</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Therapy</title>
            <description>standard UFH treatment (intravenous standard dose unfractioned heparin group)</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiac Events</title>
          <units>percentage of event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Major Adverse Cardiac Event</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Intracoronary Heparin Treatment Arm</title>
            <description>low dose intracoronary heparin treatment arm (intracoronary 1000 IU unfractioned heparin arm)</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiac Event</title>
          <units>percentage of event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Low Dose Intracoronary Heparin</title>
          <description>Low dose intracoronary heparin treatment arm</description>
        </group>
        <group group_id="E2">
          <title>Standard Therapy</title>
          <description>standard UFH treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>MI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The intraprocedural use of a heparinised flush was not controlled; however, given the maximum amount that was allowed to be used, this is not likely to have significantly affected the activated clotting times. .</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr.Hasan ARI</name_or_title>
      <organization>Bursa Postgraduate Hospital</organization>
      <phone>00902243605050 ext 1739</phone>
      <email>hasanari03@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

